TwitterLinkedInYoutubeSlideshareflickrIFPMA - Global Health Matters - BlogRSS

International Federation of Pharmaceutical Manufacturers & Associations


  • Doping in sports is a huge societal problem. No longer limited to elite athletes, it is increasingly found in amateur and school sports.
  • Abuse of medicines for sports doping purposes represents an unsafe and unapproved use of medicines and brings significant health risks.
  • IFPMA members are concerned that their medicines could be abused for sports doping purposes. They are committed to developing safe medicines and to ensuring their safe and appropriate use for the welfare of patients.
  • The IFPMA and the World Anti-Doping Agency (WADA) have joined together to combat the latest doping techniques.
  • The Joint Declaration on Cooperation in the Fight against Doping in Sports facilitates voluntary cooperation between IFPMA member companies and WADA to identify medicinal compounds with doping potential, minimize misuse of medicines still in development, improve the flow of relevant information, and facilitate development of detection methods.


Abuse of medicines to enhance performance in sports is a serious public health issue.

While some approved medicines have abuse potential, their attractiveness for doping is diminished by the fact that these products are well known and detection methods are available. However, medicinal compounds in pre-clinical or clinical development or that have been discontinued may be less well known. This might delay authorities’ awareness of their doping potential and the development of laboratory methods of detection. Thus, compounds in development can be of great interest to dopers, regardless of their side effects. It is therefore very important for the anti-doping community and the pharmaceutical industry to address this issue in a coordinated and effective way.

In 2010, the IFPMA and WADA signed a Joint Declaration on Cooperation in the Fight against Doping in Sports. This created a strong framework of collaboration and encouraged IFPMA member companies and WADA to voluntarily cooperate. These collaborations should take place on a case-by-case basis when a company-owned compound appears to have doping potential. To encourage this, the declaration draws attention to important concerns, such as confidentiality, and outlines some basic principles for managing these. The IFPMA and WADA affirm their common objective to ensure the proper use of medicines and compounds in development to protect the health of both athletes and the public at large.